Changes in Myomectomy Practice After the U.S. Food and Drug Administration Safety Communication on Power Morcellation
- 1 June 2017
- journal article
- other
- Published by Wolters Kluwer Health in Obstetrics & Gynecology
- Vol. 129 (6) , 1007-1013
Abstract
OBJECTIVE: To examine the association between the 2014 U.S. Food and Drug Administration (FDA) safety communication on power morcellation and surgical approach and morbidity after myomectomy. METHODS: In this retrospective cohort study, data were abstracted from the American College of Surgeons National Surgical Quality Improvement Program database on 3,160 myomectomies between April 2012 and December 2013 (pre-FDA) and 4,378 between April 2014 and December 2015 (post-FDA). Aims were to 1) compare rates of abdominal and laparoscopic myomectomy pre-FDA and post-FDA (primary outcome), 2) directly compare the morbidity of abdominal and laparoscopic myomectomy during each time period (secondary outcome 1), and 3) compare the morbidity after all myomectomies performed pre-FDA and post-FDA (secondary outcome 2). Adjusted means, odds ratios, and rate ratios with 95% confidence intervals were calculated using linear, logistic, and Poisson regression, respectively, adjusting for age, race, ethnicity, body mass index, and myoma burden. RESULTS: Myomectomies performed post-FDA were more likely to be abdominal (60.0%, 95% confidence interval [CI] 58.6–61.5%) than laparoscopic (40.0%, 95% CI 38.5–41.4%) as compared with myomectomies pre-FDA, which were equally divided between surgical approaches (49.1% abdominal, 95% CI 47.4–50.9% compared with 50.9% laparoscopic, 95% CI 49.1–52.6%; P<.001). When directly compared with laparoscopic myomectomy, abdominal myomectomy was associated with longer hospitalizations, higher readmission rates, and greater morbidity both pre-FDA and post-FDA (P<.05, all comparisons). Adjusted models demonstrated shorter operative times post-FDA for all myomectomies (P<.001), although composite morbidity was similar between myomectomies performed pre-FDA and post-FDA (P=.809). CONCLUSIONS: The FDA safety communication on power morcellation was associated with an 11% absolute increase in the use of abdominal myomectomy. Although morbidity is consistently higher after abdominal as compared with laparoscopic myomectomy, the increased reliance on abdominal myomectomy post-FDA did not result in clinically significant changes in morbidity in this cohort.Keywords
This publication has 15 references indexed in Scilit:
- Practice patterns and postoperative complications before and after US Food and Drug Administration safety communication on power morcellationAmerican Journal of Obstetrics and Gynecology, 2016
- Association of the U.S. Food and Drug Administration Morcellation Warning With Rates of Minimally Invasive Hysterectomy and MyomectomyObstetrics & Gynecology, 2015
- Laparoscopic myomectomy—The gold standardGynecology and Minimally Invasive Therapy, 2014
- Quality Improvement in Surgery: the American College of Surgeons National Surgical Quality Improvement Program ApproachAdvances in Surgery, 2010
- Toward Robust Information: Data Quality and Inter-Rater Reliability in the American College of Surgeons National Surgical Quality Improvement ProgramJournal of the American College of Surgeons, 2010
- Laparoscopic versus open myomectomy—A meta-analysis of randomized controlled trialsEuropean Journal of Obstetrics & Gynecology and Reproductive Biology, 2009
- Blueprint for a New American College of Surgeons: National Surgical Quality Improvement ProgramJournal of the American College of Surgeons, 2008
- “Reprint of” The normal menopause transitionMaturitas, 2008
- Successful Implementation of the Department of Veterans Affairs’ National Surgical Quality Improvement Program in the Private Sector: The Patient Safety in Surgery StudyAnnals of Surgery, 2008
- Age at natural menopause in a population-based screening cohort: the role of menarche, fecundity, and lifestyle factorsFertility and Sterility, 1997